Last checked at 9 May 2024 14:35
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Posting of Annual Report and Accounts, and Notice of AGM
Brighton, United Kingdom - 9 May 2024 - Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that the following documents are now available on the Company's website at www.destinypharma.com:
· Annual Report and Accounts of the Company for the year ended 31 December 2023
· Notice of the 2024 Annual General Meeting ("AGM") and details for voting by proxy, which is to be held at 11.00 a.m. on 12 June 2024 at the offices of Covington & Burling LLP, 22 Bishopsgate, London, EC2N 4BQ
Printed copies of both documents will be posted to shareholders today.
Immediately following the AGM at 11:00am, Destiny Pharma will host a live presentation followed by Q&A.
In order to ensure that shareholders are able to follow the proceedings of the AGM without attending in person, the Company will provide access online via the Investor Meet Company platform. However, please note that shareholders will not be able to vote online at the AGM via the platform and are therefore requested to submit their votes via proxy, as early as possible. Shareholders are invited to submit any questions for the Board to consider. Questions can be pre submitted ahead of the AGM via the Investor Meet Company Platform up until 9 a.m. the day before the AGM or submitted at any time during the AGM itself.
Shareholders that wish to attend the AGM remotely should register for the event in advance by using the following link:https://www.investormeetcompany.com/destiny-pharma-plc/register-investor
For further information, please contact:
Destiny Pharma plc
Chris Tovey, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com
FTI Consulting
Ben Atwell / Simon Conway / Michael Trace
+44 (0) 203 727 1000
destinypharma@fticonsulting.com
Shore Capital (Nominated Adviser and Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090
About Destiny Pharma
Destiny Pharma is an innovative, clinical-stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections. The company's drug development pipeline includes two late-stage assets: XF-73 nasal gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA and NTCD-M3, a microbiome-based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US.